ReviewJournal of bone oncology2025

Management of aromatase inhibitor-associated bone loss (AIBL) in women with hormone-sensitive breast cancer: An updated joint position statement of the IOF, CABS, ECTS, IEG, ESCEO, IMS, and SIOG.

Peyman Hadji et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.